Filing Details
- Accession Number:
- 0001567619-20-008539
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-04-28 14:37:44
- Reporting Period:
- 2020-04-24
- Accepted Time:
- 2020-04-28 14:37:44
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1048477 | Biomarin Pharmaceutical Inc | BMRN | Pharmaceutical Preparations (2834) | 680397820 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1197355 | J Henry Fuchs | C/O Biomarin Pharmaceutical Inc. 770 Lindaro St. San Rafael CA 94901 | President, Worldwide R&D | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Disposition | 2020-04-24 | 13,642 | $95.34 | 109,014 | No | 4 | S | Direct | |
Common Stock | Disposition | 2020-04-24 | 3,678 | $96.85 | 105,336 | No | 4 | S | Direct | |
Common Stock | Disposition | 2020-04-24 | 2,680 | $97.32 | 102,656 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct |
Footnotes
- Trade made pursuant to a 10b5-1 plan executed on March 11, 2020.
- The price in column 4 is the weighted average price. The price actually received ranged from $95.015 to $95.99. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price.
- The price in column 4 is the weighted average price. The price actually received ranged from $96.17 to $97.15. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price.
- The price in column 4 is the weighted average price. The price actually received ranged from $97.17 to $97.50. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price.